Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression

International Journal of Psychiatry in Clinical Practice

Volumn 21, Issue 2, 2017, Pages 99-103

  Rybakowski, Janusz K ^a   Permoda Osip, Agnieszka ^a   Bartkowska Sniatkowska, Alicja ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

bipolar; depression; efficacy; Ketamine

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYANOCOBALAMIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; KETAMINE; LAMOTRIGINE; LITHIUM CARBONATE; MIANSERIN; MIRTAZAPINE; OLANZAPINE; PAROXETINE; QUETIAPINE; REBOXETINE; SERTRALINE; VALPROIC ACID; VENLAFAXINE; ANTIDEPRESSANT AGENT; PSYCHOTROPIC AGENT;

ADULT; ALCOHOLISM; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BODY WEIGHT; CONTROLLED STUDY; DEPERSONALIZATION; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FAMILY HISTORY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL DISEASE; MENTAL PATIENT; MIDDLE AGED; ONSET AGE; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOPHARMACOTHERAPY; RISK FACTOR; SCORING SYSTEM; SERUM; SEX DIFFERENCE; SIDE EFFECT; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; HOSPITAL PATIENT; PSYCHOLOGY; SEX FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INPATIENTS; KETAMINE; MALE; MIDDLE AGED; PSYCHOTROPIC DRUGS; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85014678271     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651501.2017.1297834     Document Type: Article

References (27)

1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. 2000. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 47:351–354.
2. Carrier N, Kabbaj M., 2013. Sex differences in the antidepressant-like effects of ketamine. Neuropharmacology. 70:27–34.
3. Coyle CM, Laws KR., 2015. The use of ketamine as an antidepressant:a systematic review and meta-analysis. Hum Psychopharmacol. 30:152–163.
4. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, et al. 2010. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 67:793–802.
5. First MB, Spitzer RL, Gibbon M, Williams J., 1996. Structured clinical interview for DSM-IV axis I disorders, clinician version (SCID-CV). Washington, DC:American Psychiatric Press Inc.
6. Ford N, Ludbrook G, Galletly C., 2015. Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression. Aust N Z J Psychiatry. 49:1227.
7. Hartigan G., 1963. The use of lithium salts in affective disorders. Br J Psychiatry. 109:810–814.
8. Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate CA., Jr.2015. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord. 17:438–443.
9. Ketter T, Calabrese JR., 2002. Stabilization of mood from below versus above baseline in bipolar disorder:A new nomenclature. J Clin Psychiatry. 63:146–151.
10. Lambert PA, Borselli S, Marcou G, Bouchardy M, Cabrol G., 1971. Action thymoregulatrice a long terme de Depamide dans la psychose maniaco-depressive. Ann Médico-Psychol. 2:442–447.
11. Luckenbaugh DA, Ibrahim L, Brutsche N, Franco-Chaves J, Mathews D, Marquardt CA, Cassarly C, Zarate CA Jr. 2012. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. Bipolar Disord. 14:880–887.
12. Lundin NB, Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, et al. 2014. Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine. Pharmacopsychiatry. 47:141–144.
13. Mion G, Villevieille T., 2013. Ketamine pharmacology:an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 19:370–380.
14. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, et al. 2013. Antidepressant efficacy of ketamine in treatment-resistant major depression:a two-site randomized controlled trial. Am J Psychiatry. 170:1134–1142.
15. Okuma T, Kishimoto A, Inue K., 1973. Anti-manic and prophylactic effect of carbamazepine (Tegretol) on manic depressive psychosis. Folia Psychiatr Neurol Jpn. 27:283–297.
16. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS, et al. 2013. The International Society for Bipolar Disorders (ISBD) Task Force report on antidepressant use in bipolar disorders. Am J Psychiatry. 170:1249–1262.
17. Permoda-Osip A, Dorszewska J, Bartkowska-Sniatkowska A, Chlopocka-Wozniak M, Rybakowski JK., 2013. Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression. Pharmacopsychiatry. 46:227–228.
18. Permoda-Osip A, Skibinska M, Bartkowska-Sniatkowska A, Kliwicki S, Chlopocka-Wozniak M, Rybakowski JK., 2014. Factors connected with efficacy of single ketamine infusion in bipolar depression. Psychiatr Pol. 48:35–47.
19. Permoda-Osip A, Kisielewski J, Bartkowska-Sniatkowska A, Rybakowski JK., 2015. Single ketamine infusion and neurocognitive performance in bipolar depression. Pharmacopsychiatry. 48:78–79.
20. Rybakowski JK., 2007. Two generations of mood stabilizers. Int J Neuropsychopharmacol. 10:709–711.
21. Rybakowski JK., 2008. Aripiprazole joins the family of second-generation mood stabilizers. J Clin Psychiatry. 69:862–863.
22. Rybakowski JK, Dudek D, Pawlowski T, Lojko D, Siwek M, Kiejna A., 2013. Use of the Hypomania Checklist-32 and the Mood Disorder Questionnaire for detecting bipolarity in 1051 patients with major depressive disorder. Eur Psychiatry. 27:577–581.
23. Rybakowski JK, Permoda-Osip A, Skibinska M, Adamski R, Bartkowska-Sniatkowska A., 2013. Single ketamine infusion in bipolar depression resistant to antidepressants:are neurotrophins involved? Hum Psychopharmacol. 28:87–90.
24. Xu AJ, Niciu MJ, Lundin NB, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Machado-Vieira R, et al. 2015. Lithium and valproate levels do not correlate with ketamine's antidepressant efficacy in treatment-resistant bipolar depression. Neural Plast. 2015:858251.
25. Zarate CA, Tohen M, Banov MD, Weiss MK, Cole JO., 1995. Is clozapine a mood stabilizer? J Clin Psychiatry. 56:108–112.
26. Zarate CA, Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 63:856–864.
27. Zarate CA, Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA. 2012. Replication of ketamine's antidepressant efficacy in bipolar depression:a randomized controlled add-on trial. Biol Psychiatry. 71:939–946.